129,513 Shares in GSK PLC Sponsored ADR $GSK Acquired by PFA Pension Forsikringsaktieselskab

Key Points

• PFA Pension Forsikringsaktieselskab opened a new position in GSK in Q4, buying 129,513 ADR shares valued at approximately $6.385 million.
• GSK beat expectations for its most recent quarter, reporting $0.68 EPS versus a $0.64 consensus and revenue of $11.59 billion, up 6.2% year-over-year.
• The company announced a quarterly dividend of $0.44 per share (annualized $1.76, ~3.5% yield), with an ex-dividend date of May 15 and payment on July 9.

PFA Pension Forsikringsaktieselskab purchased a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 129,513 shares of the pharmaceutical company's stock, valued at approximately $6,385,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GSK. Fisher Asset Management LLC lifted its stake in shares of GSK by 2.8% during the 3rd quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company's stock worth $1,390,944,000 after acquiring an additional 889,210 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its position in GSK by 28.2% during the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company's stock valued at $4,656,000 after purchasing an additional 26,685 shares in the last quarter. Prime Capital Investment Advisors LLC raised its position in GSK by 182.7% during the 4th quarter. Prime Capital Investment Advisors LLC now owns 30,188 shares of the pharmaceutical company's stock valued at $1,480,000 after purchasing an additional 19,509 shares in the last quarter. AQR Capital Management LLC raised its position in GSK by 84.4% during the 1st quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company's stock valued at $1,559,000 after purchasing an additional 18,420 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in GSK by 146.6% during the 4th quarter. Farther Finance Advisors LLC now owns 29,529 shares of the pharmaceutical company's stock valued at $1,448,000 after purchasing an additional 17,553 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Down 1.5%

Shares of GSK stock opened at $50.85 on Tuesday. GSK PLC Sponsored ADR has a 1-year low of $35.45 and a 1-year high of $61.69. The stock's fifty day moving average price is $55.78 and its 200 day moving average price is $51.73. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. The company has a market cap of $103.19 billion, a price-to-earnings ratio of 13.22, a price-to-earnings-growth ratio of 2.63 and a beta of 0.38.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Thursday, February 5th. The pharmaceutical company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.04. GSK had a return on equity of 44.28% and a net margin of 17.82%.The firm had revenue of $11.59 billion for the quarter, compared to the consensus estimate of $8.48 billion. During the same period in the previous year, the business earned $0.23 EPS. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. On average, research analysts expect that GSK PLC Sponsored ADR will post 4.88 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a yield of 3.5%. The ex-dividend date is Friday, May 15th. GSK's payout ratio is 48.83%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. TD Cowen reiterated a "hold" rating on shares of GSK in a report on Monday, February 9th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of GSK in a report on Friday, January 16th. Barclays reiterated an "underweight" rating on shares of GSK in a report on Friday, February 20th. Weiss Ratings upgraded GSK from a "hold (c+)" rating to a "buy (b)" rating in a report on Friday. Finally, Wall Street Zen downgraded GSK from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus price target of $53.00.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.